Abstract
Carfilzomib, the first irreversible proteasome inhibitor, is used for treating multiple myeloma (MM). An increased incidence of cardiac toxicity due to carfilzomib has been reported. One proposed mechanism of cardiac adverse events is vascular endothelial effects leading to vascular dysfunction. Angiotensin II receptor blockers (ARB) are a key drug of treatment for heart failure and have efficacy for improving endothelial function. The purpose of this study is to demonstrate that adding ARB to carfilzomib contributes to reducing heart strain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
